Acrivon Therapeutics (ACRV) Financials

Acrivon Therapeutics remains a development-stage biotechnology company with no reported revenue in any of the periods provided. Its financial profile is therefore driven primarily by research spending, investment income, financing activity and cash reserves rather than operating sales.

• Operating losses improved year over year. Second-quarter 2026 net loss was $18.0 million, compared with $21.0 million in the second quarter of 2025. Total operating expenses also declined to $18.7 million from $22.6 million, led by lower research and development spending.
• Quarterly cash burn moderated. Net cash used in operating activities was $14.9 million in Q2 2026, an improvement from $16.6 million in Q2 2025 and $20.5 million in Q1 2026.
• Acrivon maintains substantial liquidity. Cash and short-term investments totaled approximately $90.0 million at June 30, 2026. Total current assets of $91.5 million substantially exceeded total current liabilities of $11.4 million.
• Debt exposure appears limited. Total liabilities were $12.4 million at the end of Q2 2026, compared with $99.1 million of total assets. The company reported no preferred stock and no commitments or contingencies in the supplied data.
• Interest and investment income continues to offset part of the burn. Acrivon generated $860,000 of interest and investment income in Q2 2026, although this was lower than the $1.7 million recorded in Q2 2025.
• Cash increased during Q2 2026, but the improvement was not generated by operations. Cash and equivalents rose from $34.1 million to $41.4 million, while total cash and short-term investments increased by approximately $1.8 million. The quarterly $7.4 million increase in cash was supported by $14.9 million of investing inflows and $7.3 million of financing inflows.
• The company’s liquidity is concentrated in short-term investments. Short-term investments were $48.5 million at June 30, 2026, exceeding cash and equivalents of $41.4 million. Investment maturities and sales have been a recurring source of cash, so reported investing inflows should not be interpreted as recurring operating revenue.
• Based on the latest quarterly operating burn, available liquidity could fund operations for roughly six quarters. This simple estimate compares approximately $90.0 million of cash and short-term investments with Q2 2026 operating cash use of $14.9 million. Actual runway could vary materially with clinical spending, trial milestones, financing activity and investment returns.
• Acrivon continues to produce recurring losses and negative operating cash flow. Net losses have persisted throughout the periods provided, while retained earnings declined from a deficit of $132.9 million in Q1 2024 to a deficit of $311.9 million in Q2 2026.
• The company remains dependent on external capital and portfolio maturities. With no revenue and consistently negative operating cash flow, future clinical development will likely require continued use of existing investments, additional financing or a combination of both. The Q2 2026 financing inflow of $7.3 million also suggests that non-operating funding remains relevant to liquidity management.

Overall, Acrivon’s balance sheet remains relatively strong for a clinical-stage biotechnology company, with low liabilities and meaningful cash and investment holdings. However, the company has not yet demonstrated commercial revenue, and its continued operating losses and cash consumption mean that clinical progress and future financing access remain central risks for shareholders.